Pharmaron Beijing Co., Ltd. Class H stock analysis
Pharmaron Beijing Co., Ltd. Class H (17Q1) Stock Price & Analysis
17Q1 Stock Chart & Stats
- Day’s Range
- EUR 3.38 - EUR 3.38
- 52-Week Range
- EUR 1.60 - EUR 3.70
- Previous Close
- EUR 3.28
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 10.04B
- Enterprise Value
- EUR 63.14B
- Total Cash (Recent Filing)
- EUR 4.03B
- Total Debt (Recent Filing)
- EUR 7.46B
- Price to Earnings (P/E)
- 45.6
- Beta
- 0.78
- Next Earnings
- Mar 29, 2027 (Est.)
- EPS Estimate
- 0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.75%
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
Robust multi-year and TTM revenue growth indicates continued demand for Pharmaron’s research, development, and manufacturing services. Sustained expansion can broaden customer relationships, improve operating scale, and support reinvestment across its integrated life-sciences platform over the next several quarters.
Integrated CRDMO Platform
An integrated CRDMO offering gives customers access to services across the drug-development lifecycle, potentially deepening relationships and increasing opportunities to capture work as programs advance. Coverage of both small molecules and biologics also supports a broad, diversified service proposition.
Reasonable Leverage And Positive Profitability
A debt-to-equity ratio of about 0.43 and a sizable equity base provide a reasonable financial foundation, while an approximately 11% TTM net margin confirms the business remains profitable. This combination supports ongoing operations and gives the company some capacity to fund its platform.
Bears Say
Margin Compression
The decline in net margin from roughly 22% to 11% shows that revenue growth has not translated into stable profitability at prior levels. Persistent compression would reduce earnings conversion, limit internal funding capacity, and make future growth less valuable if costs continue rising faster than revenue.
Negative Free Cash Flow
Negative TTM free cash flow despite positive operating cash flow indicates that investment or working-capital demands are absorbing reported earnings. If this persists, the company may have less internally generated cash for expansion, debt reduction, and shareholder returns, weakening overall earnings quality.
Rising Debt Burden
Although current leverage remains reasonable, the latest increase in total debt reduces financial flexibility and raises the importance of maintaining profitability and cash generation. Further debt growth alongside margin pressure could constrain capital allocation and increase sensitivity to weaker operating performance.
Pharmaron Beijing Co., Ltd. Class H News
17Q1 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bo Liang Lou
- Employees
- 25,088
- Website
- www.pharmaron.cn
- Address
- Building 1, Beijing, BE, 100176, CN
Pharmaron Beijing Co., Ltd. Class H (17Q1) Earnings & Revenues
17Q1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 3 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 12 | 0 | 0 |
